The actual LSD1 chemical iadademstat (Encorafenib) focuses on SOX2-driven cancers of the breast originate tissue: a prospective epigenetic therapy within luminal-B as well as HER2-positive breast cancers subtypes
https://www.selleckchem.com/products/lgx818.html